ELAN

 Elderly patients aged 70 years and older, with R/M HNSCC, classified fit by adapted geriatric evaluation, were able to receive carboplatin-based EXTREME regimen that provided benefit similar to that observed in younger patients.

 Elderly patients with R/M HNSCC, classified unfit by geriatric assessment, showed less benefit from systemic treatment with either cetuximab or methotrexate. Those with poorer ECOG performance status (PS 2) derived no benefit from systemic therapy

PERSONALIZED TREATMENT ACCORDING TO GERIATRIC ASSESSMENT IN 1ST LINE RECURRENT AND/OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CANCER (HNSCC) PATIENTS AGED 70 OR OVER.

J. Guigay, A. Auperin, C. Mertens, C. Even, L. Geoffrois, D. Cupissol, F. Rolland, C. Sire, J. Fayette, F. Peyrade, E. Blot, P. Debourdeau, L. Bozec Le Moal, O. Capitain, Y. Pointreau, C. Brard, C. Michel, D. Schwob, C. Ortholan, H. Le Caer

Présentation ESMO 2019